Digestive Diseases and Sciences

, Volume 61, Issue 6, pp 1440–1447 | Cite as

Gastrointestinal Bleeding Following LVAD Placement from Top to Bottom

  • Kelly Cushing
  • Vladimir Kushnir
DDS-GRG Mentored Reviews



Left ventricular assist devices (LVADs) are an increasingly prevalent form of mechanical support for patients with end-stage heart failure. These devices can be implanted both as a bridge to transplant and as definitive/destination therapy. Gastrointestinal (GI) bleeding is one of the most common and recalcitrant long-term complications following LVAD implantation, with an incidence approaching 30 %.


This review will discuss what is known about the pathophysiology of GI bleeding in LVADs and the currently available options for medical and/or endoscopic management.


The pathophysiology of bleeding is multifactorial, with hemodynamic alterations, acquired von Willebrand factor deficiency, and coagulopathy being most often implicated. The majority of bleeding events in this population result from angioectasias and gastroduodenal erosive disease. While these bleeding events are significant and often require transfusion therapy, they are rarely life threatening. Endoscopy remains the standard of care with upper endoscopy offering the highest diagnostic yield in these patients. However, the effectiveness of endoscopic hemostasis in this population is not well established. A small number of studies have evaluated medical therapy and alterations in LVAD settings as a means of preventing or treating bleeding with variable results.


In summary, GI bleeding with LVADs is a common occurrence and will continue to be as more LVADs are being performed for destination therapy.


Left ventricular assist device Gastrointestinal bleeding Angiodysplasia 



Kelly Cushing received the support from T32DK007130 Grant.


  1. 1.
    Mozaffarian D, Benjamin EJ, Go AS, et al. Heart disease and stroke statistics—2015 update: a report from the American Heart Association. Circulation. 2015;131:e29–e322.CrossRefPubMedGoogle Scholar
  2. 2.
    Loor G, Gonzalez-Stawinski G. Pulsatile vs. continuous flow in ventricular assist device therapy. Best Pract Res Clin Anaesthesiol. 2012;26:105–115.CrossRefPubMedGoogle Scholar
  3. 3.
    Slaughter MS, Rogers JG, Milano CA, et al. Advanced heart failure treated with continuous-flow left ventricular assist device. N Engl J Med. 2009;361:2241–2251.CrossRefPubMedGoogle Scholar
  4. 4.
    Shrode CW, Draper KV, Huang RJ, et al. Significantly higher rates of gastrointestinal bleeding and thromboembolic events with left ventricular assist devices. Clin Gastroenterol Hepatol. 2014;12:1461–1467.CrossRefPubMedGoogle Scholar
  5. 5.
    Crow S, John R, Boyle A, et al. Gastrointestinal bleeding rates in recipients of nonpulsatile and pulsatile left ventricular assist devices. J Thorac Cardiovasc Surg. 2009;137:208–215.CrossRefPubMedGoogle Scholar
  6. 6.
    Islam S, Cevik C, Madonna R, et al. Left ventricular assist devices and gastrointestinal bleeding: a narrative review of case reports and case series. Clin Cardiol. 2013;36:190–200.CrossRefPubMedGoogle Scholar
  7. 7.
    Draper KV, Huang RJ, Gerson LB. GI bleeding in patients with continuous-flow left ventricular assist devices: a systematic review and meta-analysis. Gastrointest Endosc. 2014;80:435–446.e1.Google Scholar
  8. 8.
    Aggarwal A, Pant R, Kumar S, et al. Incidence and management of gastrointestinal bleeding with continuous flow assist devices. Ann Thorac Surg. 2012;93:1534–1540.CrossRefPubMedGoogle Scholar
  9. 9.
    Jabbar HR, Abbas A, Ahmed M, et al. The incidence, predictors and outcomes of gastrointestinal bleeding in patients with left ventricular assist device (LVAD). Dig Dis Sci. (Epub ahead of print). doi: 10.1007/s10620-015-3743-4.
  10. 10.
    Marsano J, Desai J, Chang S, Chau M, Pochapin M, Gurvits GE. Characteristics of gastrointestinal bleeding after placement of continuous-flow left ventricular assist device: a case series. Dig Dis Sci. 2015;60:1859–1867.CrossRefPubMedGoogle Scholar
  11. 11.
    Sarosiek K, et al. An old problem with a new therapy: gastrointestinal bleeding in ventricular assist device patients and deep overtube-assisted enteroscopy. Asaio J. 2013;59:384–389.CrossRefPubMedGoogle Scholar
  12. 12.
    Stern DR, Kazam J, Edwards P, et al. Increased incidence of gastrointestinal bleeding following implantation of the HeartMate II LVAD. J Card Surg. 2010;25:352–356.CrossRefPubMedGoogle Scholar
  13. 13.
    Demirozu ZT, Radovancevic R, Hochman LF, et al. Arteriovenous malformation and gastrointestinal bleeding in patients with the HeartMate II left ventricular assist device. J Heart Lung Transplant. 2011;30:849–853.CrossRefPubMedGoogle Scholar
  14. 14.
    Kushnir VM, Sharma S, Ewald GA, et al. Evaluation of GI bleeding after implantation of left ventricular assist device. Gastrointest Endosc. 2012;75:973–979.CrossRefPubMedGoogle Scholar
  15. 15.
    Morgan JA, Paone G, Nemeh HW, et al. Gastrointestinal bleeding with the HeartMate II left ventricular assist device. J Heart Lung Transplant. 2012;31:715–718.CrossRefPubMedGoogle Scholar
  16. 16.
    Letsou GV, Shah N, Gregoric ID, Myers TJ, Delgado R, Frazier OH. Gastrointestinal bleeding from arteriovenous malformations in patients supported by the Jarvik 2000 axial-flow left ventricular assist device. J Heart Lung Transplant. 2005;24:105–109.CrossRefPubMedGoogle Scholar
  17. 17.
    Heyde EC. Gastrointestinal bleeding in aortic stenosis. N Engl J Med. 1958;259:196.Google Scholar
  18. 18.
    Cappell MS, Lebwohl O. Cessation of recurrent bleeding from gastrointestinal angiodysplasias after aortic valve replacement. Ann Intern Med. 1986;105:54–57.CrossRefPubMedGoogle Scholar
  19. 19.
    Warkentin TE, Moore JC, Morgan DG. Aortic stenosis and bleeding gastrointestinal angiodysplasia: is acquired von Willebrand’s disease the link? Lancet. 1992;340:35–37.CrossRefPubMedGoogle Scholar
  20. 20.
    Vincentelli A, Susen S, Le Tourneau T, et al. Acquired von Willebrand syndrome in aortic stenosis. N Engl J Med. 2003;349:343–349.CrossRefPubMedGoogle Scholar
  21. 21.
    Geisen U, Heilmann C, Beyersdorf F, et al. Non-surgical bleeding in patients with ventricular assist devices could be explained by acquired von Willebrand disease. Eur J Cardiothorac Surg. 2008;33:679–684.CrossRefPubMedGoogle Scholar
  22. 22.
    Uriel N, Pak SW, Jorde UP, et al. Acquired von Willebrand syndrome after continuous-flow mechanical device support contributes to a high prevalence of bleeding during long-term support and at the time of transplantation. J Am Coll Cardiol. 2010;56:1207–1213.CrossRefPubMedGoogle Scholar
  23. 23.
    Malehsa D, Meyer AL, Bara C, Struber M. Acquired von Willebrand syndrome after exchange of the HeartMate XVE to the HeartMate II ventricular assist device. Eur J Cardiothorac Surg. 2009;35:1091–1093.CrossRefPubMedGoogle Scholar
  24. 24.
    Baldauf C, Schneppenheim R, Stacklies W, et al. Shear-induced unfolding activates von Willebrand factor A2 domain for proteolysis. J Thromb Haemost. 2009;7:2096–2105.CrossRefPubMedGoogle Scholar
  25. 25.
    Meyer AL, Malehsa D, Budde U, Bara C, Haverich A, Strueber M. Acquired von Willebrand syndrome in patients with a centrifugal or axial continuous flow left ventricular assist device. JACC Heart Fail. 2014;2:141–145.CrossRefPubMedGoogle Scholar
  26. 26.
    Klovaite J, Gustafsson F, Mortensen SA, Sander K, Nielsen LB. Severely impaired von Willebrand factor-dependent platelet aggregation in patients with a continuous-flow left ventricular assist device (HeartMate II). J Am Coll Cardiol. 2009;53:2162–2167.CrossRefPubMedGoogle Scholar
  27. 27.
    Suarez J, Patel CB, Felker GM, Becker R, Hernandez AF, Rogers JG. Mechanisms of bleeding and approach to patients with axial-flow left ventricular assist devices. Circ Heart Fail. 2011;4:779–784.CrossRefPubMedGoogle Scholar
  28. 28.
    Elmunzer BJ, Padhya KT, Lewis JJ, et al. Endoscopic findings and clinical outcomes in ventricular assist device recipients with gastrointestinal bleeding. Dig Dis Sci. 2011;56:3241–3246.CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Meyer MM, Young SD, Sun B, Azzouz M, Firstenberg MS. Endoscopic evaluation and management of gastrointestinal bleeding in patients with ventricular assist devices. Gastroenterol Res Pract. 2012;2012:630483.CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Edwards AL, Monkemuller K, Pamboukian SV, George JF, Wilcox CM, Peter S. Utility of double-balloon enteroscopy in patients with left ventricular assist devices and obscure overt gastrointestinal bleeding. Endoscopy. 2014;46:986–991.CrossRefPubMedGoogle Scholar
  31. 31.
    Gerson LB, Fidler JL, Cave DR, Leighton JA. ACG clinical guideline: diagnosis and management of small bowel bleeding. Am J Gastroenterol. 2015;110:1265–1287.CrossRefPubMedGoogle Scholar
  32. 32.
    Khashab MA, Pasha SF, Muthusamy VR, et al. The role of deep enteroscopy in the management of small-bowel disorders. Gastrointest Endosc. 2015;82:600–607.CrossRefPubMedGoogle Scholar
  33. 33.
    Truss WD, Weber F, Pamboukian SV, Tripathi A, Peter S. Early implementation of video capsule enteroscopy in patients with left ventricular assist devices and obscure gastrointestinal bleeding. Asaio J. 2016;62:40–45.CrossRefPubMedGoogle Scholar
  34. 34.
    Daas AY, Small MB, Pinkas H, Brady PG. Safety of conventional and wireless capsule endoscopy in patients supported with nonpulsatile axial flow Heart-Mate II left ventricular assist device. Gastrointest Endosc. 2008;68:379–382.CrossRefPubMedGoogle Scholar
  35. 35.
    Harris LA, Hansel SL, Rajan E, et al. Capsule endoscopy in patients with implantable electromedical devices is safe. Gastroenterol Res Pract. 2013;2013:959234.CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    Barbara DW, Olsen DA, Pulido JN, et al. Periprocedural management of 172 gastrointestinal endoscopies in patients with left ventricular assist devices. Asaio J. 2015;61:670–675.CrossRefPubMedGoogle Scholar
  37. 37.
    Kushnir VM, De Mondesert LM, Joseph S, Ewald GA, Silvestry S, Edmundowicz SA. Incidence of sedation related adverse events (Srae) during endoscopy in patients supported by continuous flow left ventricular assist devices (LVAD). Gastrointest Endosc. 2013;77:AB477.Google Scholar
  38. 38.
    Goudra BG, Singh PM. Anesthesia for gastrointestinal endoscopy in patients with left ventricular assist devices: initial experience with 68 procedures. Ann Card Anaesth. 2013;16:250–256.CrossRefPubMedGoogle Scholar
  39. 39.
    Wever-Pinzon O, Selzman CH, Drakos SG, et al. Pulsatility and the risk of nonsurgical bleeding in patients supported with the continuous-flow left ventricular assist device HeartMate II. Circ Heart Fail. 2013;6:517–526.CrossRefPubMedGoogle Scholar
  40. 40.
    Katz JN, Adamson RM, John R, et al. Safety of reduced anti-thrombotic strategies in HeartMate II patients: a one-year analysis of the US-TRACE Study. J Heart Lung Transplant. 2015;34:1542–1548.CrossRefPubMedGoogle Scholar
  41. 41.
    Stulak JM, Lee D, Haft JW, et al. Gastrointestinal bleeding and subsequent risk of thromboembolic events during support with a left ventricular assist device. J Heart Lung Transplant. 2014;33:60–64.CrossRefPubMedGoogle Scholar
  42. 42.
    Kamdar F, Eckman P, John R. Safety of discontinuation of anti-coagulation in patients with continuous-flow left ventricular assist devices. J Heart Lung Transplant. 2014;33:316–318.CrossRefPubMedGoogle Scholar
  43. 43.
    Szilagyi A, Ghali MP. Pharmacological therapy of vascular malformations of the gastrointestinal tract. Can J Gastroenterol. 2006;20:171–178.CrossRefPubMedPubMedCentralGoogle Scholar
  44. 44.
    Rennyson SL, Shah KB, Tang DG, et al. Octreotide for left ventricular assist device-related gastrointestinal hemorrhage: can we stop the bleeding? Asaio J. 2013;59:450–451.CrossRefPubMedGoogle Scholar
  45. 45.
    Coutance G, Saplacan V, Belin A, Repesse Y, Buklas D, Massetti M. Octreotide for recurrent intestinal bleeding due to ventricular assist device. Asian Cardiovasc Thorac Ann. 2014;22:350–352.CrossRefPubMedGoogle Scholar
  46. 46.
    Dang G, Grayburn R, Lamb G, Umpierrez De Reguero A, Gaglianello N. Octreotide for the management of gastrointestinal bleeding in a patient with a HeartWare left ventricular assist device. Case Rep Cardiol. 2014;2014:826453.PubMedPubMedCentralGoogle Scholar
  47. 47.
    Loyaga-Rendon RY, Hashim T, Tallaj JA, et al. Octreotide in the management of recurrent gastrointestinal bleed in patients supported by continuous flow left ventricular assist devices. Asaio J. 2015;61:107–109.CrossRefPubMedGoogle Scholar
  48. 48.
    Hayes HM, Dembo LG, Larbalestier R, O'Driscoll G. Management options to treat gastrointestinal bleeding in patients supported on rotary left ventricular assist devices: a single-center experience. Artif Organs. 2010;34:703–706.CrossRefPubMedGoogle Scholar
  49. 49.
    Shurafa M, Kamboj G. Thalidomide for the treatment of bleeding angiodysplasias. Am J Gastroenterol. 2003;98:221–222.CrossRefPubMedGoogle Scholar
  50. 50.
    Alam MA, Sami S, Babu S. Successful treatment of bleeding gastro-intestinal angiodysplasia in hereditary haemorrhagic telangiectasia with thalidomide. BMJ Case Rep. 2011;2011:1–3.Google Scholar
  51. 51.
    Ge ZZ, Chen HM, Gao YJ, et al. Efficacy of thalidomide for refractory gastrointestinal bleeding from vascular malformation. Gastroenterology. 2011;141:1629–37.e1-4.Google Scholar
  52. 52.
    Chen CH, Hsu HH, Hu RH, Lee PH, Ho CM. Long-term therapy with thalidomide in hereditary hemorrhagic telangiectasia: case report and literature review. J Clin Pharmacol. 2012;52:1436–1440.CrossRefPubMedGoogle Scholar
  53. 53.
    Ray R, Kale PP, Ha R, Banerjee D. Treatment of left ventricular assist device-associated arteriovenous malformations with thalidomide. Asaio J. 2014;60:482–483.CrossRefPubMedGoogle Scholar
  54. 54.
    Draper K, Kale P, Martin B, Cordero K, Ha R, Banerjee D. Thalidomide for treatment of gastrointestinal angiodysplasia in patients with left ventricular assist devices: case series and treatment protocol. J Heart Lung Transplant. 2015;34:132–134.CrossRefPubMedGoogle Scholar
  55. 55.
    Fischer Q, Huisse MG, Voirot G, et al. Von Willebrand factor, a versatile player in gastrointestinal bleeding in left ventricular assist device recipients? Transfusion. 2015;55:51–54.CrossRefPubMedGoogle Scholar
  56. 56.
    Botero JP, Pruthi RK. Refractory bleeding from intestinal angiodysplasias successfully treated with danazol in three patients with von Willebrand disease. Blood Coagul Fibrinolysis. 2013;24:884–886.CrossRefPubMedGoogle Scholar
  57. 57.
    Schettle SD, Pruthi RK, Pereira NL. Continuous-flow left ventricular assist devices and gastrointestinal bleeding: potential role of danazol. J Heart Lung Transplant. 2014;33:549–550.CrossRefPubMedGoogle Scholar
  58. 58.
    Hasin T, Marmor Y, Kremers W, et al. Readmissions after implantation of axial flow left ventricular assist device. J Am Coll Cardiol. 2013;61:153–163.CrossRefPubMedGoogle Scholar
  59. 59.
    Raymer DS, Nassif ME, Amornsawadwattana S, et al. Outpatient management of gastrointestinal bleeding in patients with continuous-flow left ventricular assist devices. J Card Fail. 2014;20:084.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2016

Authors and Affiliations

  1. 1.Department of GastroenterologyWashington UniversitySt. LouisUSA

Personalised recommendations